Aldeyra Therapeutics, Inc.

NasdaqCM:ALDX Stok Raporu

Piyasa değeri: US$294.2m

Aldeyra Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Aldeyra Therapeutics CEO'su Todd Brady, Jan2012 tarihinde atandı, in görev süresi 12.83 yıldır. in toplam yıllık tazminatı $ 3.68M olup, şirket hissesi ve opsiyonları dahil olmak üzere 15.8% maaş ve 84.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.94% ine doğrudan sahiptir ve bu hisseler $ 5.71M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 11.3 yıldır.

Anahtar bilgiler

Todd Brady

İcra Kurulu Başkanı

US$3.7m

Toplam tazminat

CEO maaş yüzdesi15.8%
CEO görev süresi12.8yrs
CEO sahipliği1.9%
Yönetim ortalama görev süresi3.8yrs
Yönetim Kurulu ortalama görev süresi11.3yrs

Son yönetim güncellemeleri

Recent updates

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Jun 21
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?

Feb 16
Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?

Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?

Nov 06
Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Mar 26
Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Nov 19
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?

Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment

Sep 14

Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization

Aug 04

Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?

Aug 03
Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Debt In A Risky Way?

Aldeyra says trial for dry eye disease candidate reached key goals

Jul 12

Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Apr 19
Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?

Aldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming Catalysts

Feb 17

Aldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In Reproxalap

Dec 23

CEO Tazminat Analizi

Todd Brady'un ücretlendirmesi Aldeyra Therapeutics'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$45m

Jun 30 2024n/an/a

-US$38m

Mar 31 2024n/an/a

-US$30m

Dec 31 2023US$4mUS$581k

-US$38m

Sep 30 2023n/an/a

-US$46m

Jun 30 2023n/an/a

-US$52m

Mar 31 2023n/an/a

-US$61m

Dec 31 2022US$3mUS$559k

-US$62m

Sep 30 2022n/an/a

-US$65m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$63m

Dec 31 2021US$3mUS$547k

-US$58m

Sep 30 2021n/an/a

-US$53m

Jun 30 2021n/an/a

-US$46m

Mar 31 2021n/an/a

-US$39m

Dec 31 2020US$2mUS$544k

-US$38m

Sep 30 2020n/an/a

-US$39m

Jun 30 2020n/an/a

-US$49m

Mar 31 2020n/an/a

-US$55m

Dec 31 2019US$4mUS$523k

-US$61m

Sep 30 2019n/an/a

-US$58m

Jun 30 2019n/an/a

-US$50m

Mar 31 2019n/an/a

-US$46m

Dec 31 2018US$3mUS$506k

-US$39m

Sep 30 2018n/an/a

-US$35m

Jun 30 2018n/an/a

-US$29m

Mar 31 2018n/an/a

-US$26m

Dec 31 2017US$2mUS$473k

-US$22m

Tazminat ve Piyasa: Todd 'nin toplam tazminatı ($USD 3.68M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.45M ).

Tazminat ve Kazançlar: Todd şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Todd Brady (52 yo)

12.8yrs

Görev süresi

US$3,684,651

Tazminat

Dr. Todd C. Brady, M.D., Ph D., served as a Director at F-star Therapeutics, Inc from November 20, 2020 to March 2023. He has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. si...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Todd Brady
CEO, President & Director12.8yrsUS$3.68m1.94%
$ 5.7m
Stephen Machatha
Chief Development Officer3.8yrsUS$1.59m0.19%
$ 552.1k
Michael Alfieri
Principal Financial & Accounting Officerless than a yearVeri yokVeri yok
David Burke
Head of Investor Relationsno dataVeri yokVeri yok
Laura Nichols
Operations Managerno dataVeri yokVeri yok

3.8yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: ALDX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Todd Brady
CEO, President & Director19.8yrsUS$3.68m1.94%
$ 5.7m
Richard Douglas
Independent Chair of the Board8.2yrsUS$221.98k0.21%
$ 617.5k
Ben Bronstein
Independent Director14.4yrsUS$190.40k0.047%
$ 139.6k
Gary Phillips
Independent Director15.5yrsUS$194.07k0.025%
$ 73.2k
Martin Joyce
Independent Director11.1yrsUS$195.66k0.040%
$ 118.4k
Neal Walker
Independent Director11.4yrsUS$174.22k0.027%
$ 78.3k
Jay Duker
Member of Retina Segment Scientific Advisory Boardno dataVeri yokVeri yok
Paul Karpecki
Member of Anterior Segment Scientific Advisory Board4.8yrsVeri yokVeri yok
John Sheppard
Member of Anterior Segment Scientific Advisory Boardno dataVeri yokVeri yok
Nancy Miller-Rich
Independent Director4.8yrsUS$174.22k0%
$ 0
Victor Perez
Member of Anterior Segment Scientific Advisory Boardno dataVeri yokVeri yok
David Chu
Member of Anterior Segment Scientific Advisory Boardno dataVeri yokVeri yok

11.3yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ALDX 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 11.3 yıldır).